A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

Stephen S Lim, Theo Vos, Abraham D Flaxman, +203

The Lancet

Epidemiologic ResearchRisk AnalysisInjury PreventionHealth StudiesPreventive Medicine +15

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova, +12

The Lancet

Surgical OncologyChemotherapy Versus ChemotherapyGastrointestinal OncologyMedicineGastroenterology +6

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

Ganesh Raghu, Harold R. Collard, Jim Egan, +30

American Journal of Respiratory and Critical Care Medicine

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Chetan Bettegowda, Mark Sausen, Rebecca Leary, +60

Science Translational Medicine

Dna AnalysisPathologyVarious Cancer TypesNucleic Acid BiomarkersTumor Biology +15

Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

Laura Evans, Andrew Rhodes, Waleed Alhazzani, +57

Intensive Care Medicine

Critical Care ManagementAcute CarePatient SafetyInternational HealthSepsis +5

Genetic effects on gene expression across human tissues

Nature

GeneticsGenomicsGene Expression ProfilingGenome-wide Association StudyGenetic Analysis +14

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Luca Richeldi, Roland M. du Bois, Ganesh Raghu, +20

New England Journal of Medicine

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, +18

The Lancet

HepatologyMedicineExpansion TrialLiver CancerAdvanced Hepatocellular Carcinoma +7

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, +17

New England Journal of Medicine

Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome

Kiichi Nakahira, Jeffrey A. Haspel, Vijay Rathinam, +10

Nature Immunology

InflammationNalp3 InflammasomeMitophagyCell AutophagyAutoimmune Disease +13